Hemophilia Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Hemophilia Pipeline Outlook Report
Key Takeaways from the Hemophilia Pipeline Report
In July 2025, Novo Nordisk A/S announced a study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector.
In July 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study.
In July 2025, Regeneron Pharmaceuticals announced a study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy.
DelveInsight's Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment.
The leading Hemophilia Companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
Promising Hemophilia Pipeline Therapies such as NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others.
Discover how the Hemophilia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Hemophilia Clinical Trials and Studies
Hemophilia Emerging Drugs Profile
SerpinPC: Centessa Pharmaceuticals
SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data.
Fitusiran: Alnylam Pharmaceuticals
Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia.
ASC 618: ASC Therapeutics
ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ASC618. The program received IND clearance from the U.S. Food and Drug Administration.
The Hemophilia Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia Treatment.
Hemophilia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hemophilia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia market.
Get a detailed analysis of the latest innovations in the Hemophilia Pipeline. Explore DelveInsight's expert-driven report today! @ Hemophilia Unmet Needs
Hemophilia Companies
Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Hemophilia Developments @ Hemophilia Market Drivers and Barriers, and Future Perspectives
Scope of the Hemophilia Pipeline Report
Coverage- Global
Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
Hemophilia Pipeline Therapies- NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others.
Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Hemophilia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Hemophilia Emerging Drugs and Major Companies
Table of Contents
Introduction
Executive Summary
Hemophilia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hemophilia– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Fitusiran: Alnylam Pharmaceuticals
Mid Stage Products (Phase II)
SerpinPC: Centessa Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company Name
Preclinical and Discovery Stage Products
Drug name: Company Name
Inactive Products
Hemophilia Key Companies
Hemophilia Key Products
Hemophilia- Unmet Needs
Hemophilia- Market Drivers and Barriers
Hemophilia- Future Perspectives and Conclusion
Hemophilia Analyst Views
Hemophilia Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hemophilia-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
42 minutes ago
- Globe and Mail
Microsoft Cloud and AI Revenue Soar
Microsoft (NASDAQ:MSFT) reported fourth-quarter fiscal 2025 earnings on July 29, 2025, delivering $76.4 billion in revenue, up 18% year-over-year in constant currency, and $3.65 in earnings per share, up 22% year over year, both in constant currency. Strong results were driven by 25% year-over-year growth in Microsoft Cloud revenue (in constant currency), $75 billion in Azure annual revenue, up 34% year-over-year for fiscal 2025 (period ended June 30, 2025), record commercial bookings exceeding $100 billion, up 30% year-over-year for fiscal 2025, and expanding adoption of AI and Copilot products across enterprise and consumer segments. This summary highlights strategic milestones in cloud, AI monetization, and capital allocation that are crucial for long-term investors. Azure growth and AI platform scale drive MSFT outperformance Microsoft Cloud's annual revenue reached $168 billion, up 23% year-over-year, while Azure expanded global infrastructure to more than 400 data centers across 70 regions. Azure's buildout included more than two gigawatts of new data center capacity, and the company led in liquid cooling capabilities for AI-first workloads. "Azure surpassed $75 billion in annual revenue, up 34% driven by growth across all workloads. We continue to lead the AI infrastructure wave and took share every quarter this year. We opened new data centers across six continents and now have over 400 data centers across 70 regions, more than any other cloud provider. There is a lot of talk in the industry about building the first gigawatt and multi-gigawatt data centers. We stood up more than two gigawatts of new capacity over the past twelve months alone, and we continue to scale our own data center capacity faster than any other competitor. Every Azure region is now AI-first. All of our regions can now support liquid cooling, increasing the fungibility and the flexibility of our fleet. And we are driving and riding a set of compounding S-curves across silicon systems and models to continuously improve efficiency and performance for our customers." -- Satya Nadella, Chairman and Chief Executive Officer Microsoft's unmatched expansion of hyperscale infrastructure positions it to capture accelerating enterprise and cloud-native migration while securing early leadership in AI-enabled workloads, underpinned by significant cost and efficiency improvements that support long-term margin durability. AI monetization accelerates with cross-stack product integration Paid commercial seats for Microsoft 365 rose 6% year-over-year, GitHub Copilot Enterprise customers increased 75% quarter-over-quarter, and Microsoft's Copilot apps have surpassed 100 million monthly active users, reflecting rapid adoption. Foundry is already used by 80% of the Fortune 500, and Foundry is now used by 14,000 customers to build agents, highlighting cross-industry traction. "Our family of Copilot apps has surpassed 100 million monthly active users across commercial and consumer. And when you take a broader look at the engagement of AI features across our products, we have over 800 million monthly active users. Microsoft 365 Copilot is becoming the new way to organize, work, and workflow and work artifacts. We rolled out our biggest update to Microsoft 365 Copilot to date this quarter, bringing together chat, search, create notebooks, as well as agents into one intuitive scaffolding. With this innovation and continued product improvements, we are seeing real momentum. Customers continue to adopt Copilot at a faster rate than any other new Microsoft 365 suite with strong usage intensity as shown by our week-over-week retention. And we saw the largest quarter of seat ads since launch with a record number of customers returning to buy more seats." -- Satya Nadella, Chairman and Chief Executive Officer Microsoft's success in embedding and monetizing AI -- spanning Copilot, Foundry, Fabric, and GitHub -- broadens the recurring revenue base and sets the stage for future pricing power and upsell opportunities within both enterprise and consumer cloud ecosystems. Contracted backlog supports sustained CapEx and margin discipline Commercial remaining performance obligation (RPO) climbed to $368 billion, up 35% year-over-year, with 35% of commercial remaining performance obligation recognized as revenue within 12 months, up 21% year-over-year. The company achieved a 45% operating margin (up two percentage points year-over-year) for the full fiscal year despite higher capital expenditures, demonstrating operational leverage. Management guided to capital expenditure moderation in fiscal 2026 (period ending June 30, 2026) with a higher mix of short-lived assets, projecting stable operating margins amid ongoing capacity investments in fiscal 2026 and cloud demand outstripping supply. "We have $368 billion of contracted backlog we need to deliver, not just across Azure, but across the breadth of the Microsoft Cloud. So in terms of feeling good, about the ROI and the growth rates and the correlation I feel very good that the spend that we're making is correlated to basically contracted on the books business. That we need to deliver and we need the teams to execute at their very best to get the capacity in place. As quickly and effectively as they can. And so when you look we've talked about the growth rate declining year over year (as discussed on the Q4 FY2025 earnings call; Microsoft reports on a fiscal year basis). But at its core, our investments, particularly in short-lived assets, like servers, GPUs, CPUs, networking storage, is just really correlated to the backlog we see and the curve of demand." -- Amy Hood, Chief Financial Officer Microsoft's robust contractual backlog provides clear forward revenue visibility, validating the prudence of elevated capital expenditures and reducing the risk of overbuild while supporting capital allocation that maximizes long-term shareholder value. Looking ahead Management expects fiscal 2026 to deliver double-digit revenue and operating income growth, driven by sustained demand for cloud and AI offerings and underpinned by a contracted RPO of $368 billion. Capital expenditures for the first quarter of fiscal 2026 are projected to exceed $30 billion, reflecting continued capacity buildout to meet demand, with Azure revenue growth forecast at approximately 37% year-over-year in constant currency for the first quarter of fiscal 2026. Operating margins are expected to remain stable year-over-year for fiscal 2026, and the effective tax rate is expected to rise to 19%-20% for fiscal 2026. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025 This article was created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. The Motley Fool has positions in and recommends Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
an hour ago
- Globe and Mail
Vitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, ' Vitiligo Pipeline Insight, 2025 ' report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Vitiligo pipeline landscape. It covers the Vitiligo pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vitiligo pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Vitiligo Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Vitiligo Pipeline Outlook Report Key Takeaways from the Vitiligo Pipeline Report In August 2025, Incyte Corporation announced a study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo. In July 2025, Clinuvel Inc. conducted a CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone. DelveInsight's Vitiligo pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Vitiligo treatment. The leading Vitiligo Companies such as Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others. Promising Vitiligo Pipeline Therapies such as Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others. Discover how the Vitiligo treatment paradigm is evolving. Access DelveInsight's in-depth Vitiligo Pipeline Analysis for a closer look at promising breakthroughs @ Vitiligo Clinical Trials and Studies Vitiligo Emerging Drugs Profile Afamelanotide: Clinuvel, Inc. Afamelanotide, developed by Clinuvel, Inc., is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) designed to promote skin pigmentation in individuals with vitiligo. It works by activating melanocortin 1 receptors (MC1R) on melanocytes, stimulating melanin production and distribution in depigmented areas of the skin. Afamelanotide is administered via a subcutaneous implant, offering a systemic approach that may enhance repigmentation, particularly when used in combination with controlled UV light therapy. Its mechanism addresses the underlying pigment loss in vitiligo, aiming to restore skin tone more uniformly and effectively. Currently, the drug is in Phase III stage of its development for the treatment of Vitiligo. VYN201: Vyne Therapeutics Inc. Repibresib is a pan-bromodomain BET inhibitor designed to be locally administered as a 'soft' drug to address diseases involving multiple, diverse inflammatory cell signaling pathways, while providing low systemic exposure. BET proteins play a key role in regulating gene transcription via epigenetic interactions ('reading'). Recent research has identified a key role for these proteins in regulating activation of immune cells, including T cells and B cells, and subsequent inflammatory and fibrotic processes. As epigenetic readers, BET proteins regulate the recruitment of transcriptional factors that are key to the production of several pro-inflammatory cytokines. BET inhibitors have the potential to treat a range of immuno-inflammatory and fibrotic diseases by blocking pro-inflammatory cytokine transcription, with additional potential in myeloproliferative neoplastic disorders. In addition to demonstrating clinical proof-of-concept in vitiligo, repibresib has produced consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity in several preclinical models (using several different routes of administration). Currently, the drug is in Phase II stage of its development for the treatment of Vitiligo. FB102: Forte Biosciences, Inc. FB102 is a proprietary molecule with potentially broad autoimmune and autoimmune-related applications. The Company's FB102 program aims to address key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. Significant reductions in NK cell pharmacodynamic marker of FB102 mechanism was observed supporting the in vitro as well as the NHP data and mechanism of action of FB102. A phase 1 healthy volunteer SAD/MAD study was successfully completed and demonstrated a good safety profile. Currently, the drug is in Phase I stage of its development for the treatment of Vitiligo. The Vitiligo Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment. Vitiligo Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market. Get a detailed analysis of the latest innovations in the Vitiligo pipeline. Explore DelveInsight's expert-driven report today! @ Vitiligo Unmet Needs Vitiligo Companies Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others. Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Vitiligo Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Vitiligo Therapies and key Developments @ Vitiligo Market Drivers and Barriers, and Future Perspectives Scope of the Vitiligo Pipeline Report Coverage- Global Vitiligo Companies- Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others. Vitiligo Pipeline Therapies- Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others. Vitiligo Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Vitiligo Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Vitiligo drug development? Find out in DelveInsight's exclusive Vitiligo Pipeline Report—access it now! @ Vitiligo Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Vitiligo: Overview Pipeline Therapeutics Therapeutic Assessment Vitiligo– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Afamelanotide: Clinuvel, Inc. Mid Stage Products (Phase II) VYN201: Vyne Therapeutics Inc. Early Stage Products (Phase I) FB102: Forte Biosciences, Inc. Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Vitiligo Key Companies Vitiligo Key Products Vitiligo- Unmet Needs Vitiligo- Market Drivers and Barriers Vitiligo- Future Perspectives and Conclusion Vitiligo Analyst Views Vitiligo Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Globe and Mail
an hour ago
- Globe and Mail
Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Investors with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers and acquirers of Novo Nordisk A/S (NYSE: NVO) securities between May 7, 2025 and July 28, 2025, both dates inclusive (the 'Class Period'). Novo Nordisk is a pharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Novo Nordisk A/S (NYSE: NVO) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo Nordisk's growth potential. Notably, Novo Nordisk's asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood that such patients would switch to Novo Nordisk's branded alternatives. Further, defendants greatly overstated the potential GLP-1 market or otherwise, Novo's capability to penetrate said markets to achieve continued growth. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Novo Nordisk. Investors who want to serve as lead plaintiff for the class must file their motions with the court by September 30, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
